ArticleBMC gastroenterology2023

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.

Sae Yumita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.